AZNAstraZenecaRunning, no new patients
Study for AZD4360 in Participants With Advanced Solid Tumours
Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract Cancer · Pancreatic Ductal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 31 (final count)
- Started
- Apr 29, 2025
- Main results expected
- Mar 31, 2027
- Fully finished
- Dec 16, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360
Measured over: Through study completion, up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06921928 · record last updated 2026-07-31 · checked 2026-11-09 15:47 UTC